
SOPH Stock Forecast & Price Target
SOPH Analyst Ratings
Bulls say
Sophia Genetics is a financially stable company that has shown significant growth and success, with a diverse and growing customer base due to their cutting-edge AI-driven genomics platform. Their recent partnerships and planned applications could drive further revenue and market expansion. With a strong presence in multiple countries and a recurring revenue model, SOPHiA is in a good position to achieve profitability and continue to grow in the rapidly evolving field of data-driven medicine.
Bears say
Sophia Genetics is a data-driven healthcare technology company that offers cloud-based diagnostic analysis solutions for life sciences research and patient care. While the company has a global presence and impressive partnerships with prestigious cancer centers, there are concerns surrounding their ability to scale sales and marketing cost-effectively, sustain and grow customer relationships, and effectively penetrate global markets with diverse data. Additionally, the company is not yet profitable, and there is uncertainty about if and when they will achieve profitability. While the company's innovative platform and partnerships are notable, they do face competition from centralized testing providers and platform players.
This aggregate rating is based on analysts' research of Sophia Genetics SA and is not a guaranteed prediction by Public.com or investment advice.
SOPH Analyst Forecast & Price Prediction
Start investing in SOPH
Order type
Buy in
Order amount
Est. shares
0 shares